To whom it may concern

Title of Study: “Real-Life Data on the Utilization Pattern and Safety Profile of Infliximab Biosimilar CT-P13 (Remsima®) in Inflammatory Bowel Disease”

Principal Investigator: José María Huguet

Servicio de Patología Digestiva.
Hospital General Universitario de Valencia (Valencia, Spain)

This letter is to confirm that the statistical analysis of this study was performed by Joaquin Peña Siles and Jose Antonio Parejo Maestre from University of Seville.

Please, do not hesitate to contact me for any queries you may have.

Sincerely,

Joaquin Peña Siles PhD, MBA
Prof. Researcher University of Seville
Dpto. Lenguajes y Sistemas Informáticos.
649 427 310